Hikal Ltd (HIKAL) is currently trading at 228.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hikal Limited is an Indian fine chemicals and CDMO company supplying APIs, advanced intermediates, crop protection actives, animal health APIs and specialty chemicals globally, operating five manufacturing sites and an R&T centre with a focus on contract development and manufacturing services for global innovators and customers across Americas, Europe, Japan, LATAM and RoW. Q3 FY26 marked a clear operational recovery for Hikal Limited after regulatory remediation: consolidated revenue recovered to INR494 crore and EBITDA expanded to INR83 crore, driven by resumed pharmaceutical supplies, improved capacity utilization and remediation largely completed at the inspected facility, restoring near‑term commercial momentum. Strategic investments made over the past 12–18 months — including a High‑Potency API (HPAPI) laboratory, a new pilot plant and two multipurpose facilities — are now operational, materially enhancing Hikal Limited’s differentiated CDMO positioning for oncology and other high‑barrier small molecules and improving medium‑term revenue visibility. The Crop Protection division faces structural pricing pressure from China and global overcapacity, prompting Hikal Limited to accelerate portfolio diversification into Personal Care and Specialty Chemicals (HiZenn, HiFend) with commercialisation expected to meaningfully contribute to revenues in FY27 and beyond. Balance sheet and cash flows show improving discipline: 9M FY26 operating cash generation remained robust despite a temporary P&L impact from a one‑time labour code exceptional item, with targeted, contract‑led capex and a management commitment to reduce net debt as operating leverage returns.

Over the past 52 weeks, Hikal Ltd has traded between a low of ₹145.95 and a high of ₹282.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hikal Ltd has a market capitalization of approximately 2,787.83. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hikal Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -82.48 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,787.83 Cr, Hikal Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hikal Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hikal Ltd is -82.48. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Hikal’s 38th AGM is scheduled for Wednesday, September 23, 2026 at 11:30 a.m. (IST) and will be conducted via VC/OAVM, with the deemed venue as its registered office in Mumbai.

Hikal reported a standalone net loss of ₹7.5 crore (₹75 million) for the quarter ended June 30, 2026.

Hikal reported Q4 FY25 revenue of ₹552 crore and EBITDA of ₹123 crore, with EBITDA margin improving to about 22.4% (also cited as 22.3%).